Evidence map›Paper›PMID 25552705›Full record

Trial reportHaematologica2015

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.

Patrice Chevallier, Francoise Huguet, Emmanuel Raffoux, Anne Etienne, Thibaut Leguay, Francoise Isnard, Nelly Robillard, Thierry Guillaume, Jacques Delaunay, Aude Charbonnier and 6 more

Abstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Targeted Therapy in Acute Lymphoblastic Leukaemia.Journal of personalized medicine · 2021
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Patrice ChevallierHematology Department, CHU Hotel-Dieu, Nantes patrice.chevallier@chu-nantes.fr.
Francoise HuguetHematology Department, CHU, Toulouse.
Emmanuel RaffouxHematology Department, Hôpital Saint-Louis, Paris.
Anne EtienneHematology Department, Institut Paoli-Calmette, Marseille.
Thibaut LeguayHematology Department, CHU, Bordeaux.
Francoise IsnardHematology Department, Hopital Saint-Antoine, Paris.
Nelly RobillardHematology/Biology Department, CHU Hotel-Dieu, Nantes, France.
Thierry GuillaumeHematology Department, CHU Hotel-Dieu, Nantes.
Jacques DelaunayHematology Department, CHU Hotel-Dieu, Nantes.
Aude CharbonnierHematology Department, Institut Paoli-Calmette, Marseille.
Arnaud PigneuxHematology Department, CHU, Bordeaux.
Pierre PeterlinHematology Department, CHU Hotel-Dieu, Nantes.
Marie C BenéHematology/Biology Department, CHU Hotel-Dieu, Nantes, France.
William A WegenerImmunomedics, Inc., Morris Plains, NJ, USA.
David M GoldenbergImmunomedics, Inc., Morris Plains, NJ, USA.
Hervé DombretHematology Department, Hôpital Saint-Louis, Paris.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneHumansPrecursor B-Cell Lymphoblastic Leukemia-LymphomaRecurrenceSialic Acid Binding Ig-like Lectin 2Treatment OutcomeVincristineAntibodies, Monoclonal, HumanizedDexamethasoneepratuzumabSialic Acid Binding Ig-like Lectin 2VincristineB-ALLCD22chemoimmunotherapyepratuzumabminimal residual diseaseolder patientsrefractoryrelapse

Identifiers

PMID25552705
PMCPMC4380733

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.